Ranolazine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Stable angina
Adult: Initially, 375 mg bid, increase after 2-4 wk to 500 mg bid. Max: 750 mg bid.
Elderly: Dose titration needed.
Renal Impairment
Mild to moderate (CrCl 30-80 mL/min): Dose titration needed. Severe (CrCl <30 mL/min): Contraindicated.
Hepatic Impairment
Mild: Dose titration needed. Moderate to severe: Contraindicated.
Cách dùng
May be taken with or without food.
Chống chỉ định
Concomitant admin w/ potent CYP3A4 inhibitors, CYP3A4 inducers and class 1A or class III antiarrhythmics other than amiodarone. Moderate to severe hepatic and severe renal impairment (CrCl <30 mL/min).
Thận trọng
Patient w/ history of long QT syndrome, known acquired QT interval prolongation, moderate to severe CHF (NYHA Class III-IV), low wt (<60 kg). Mild hepatic and mild to moderate renal impairment (CrCl 30-80 mL/min). Elderly. Pregnancy and lactation.
Phản ứng phụ
QT interval prolongation, acute renal failure, nausea, constipation, dizziness, headache, palpitations, tinnitus, vertigo, dry mouth, abdominal pain, vomiting, peripheral oedema, dyspnoea, bradycardia, haematuria, paraesthesia, hypotension, blurred vision.
Thông tin tư vấn bệnh nhân
May impair ability to drive or operate machinery.
MonitoringParameters
Baseline and follow up ECG to evaluate QT interval; monitor renal function in patients w/ moderate to severe renal impairment, BP in patients w/ renal dysfunction; serum K levels.
Quá liều
Symptoms: Dizziness, nausea, vomiting, diplopia, lethargy, syncope, severe tremor, incoordination, dysplasia, hallucination. Management: Symptomatic and supportive treatment.
Tương tác
Increased plasma levels w/ moderate CYP3A4 inhibitors (e.g. diltiazem, fluconazole, erythromycin), P-glycoprotein inhibitors (e.g. verapamil, ciclosporin) and CYP2D6 inhibitors (e.g. paroxetine). May increase plasma digoxin concentrations. May increase risk of rhabdomyolysis w/ simvastatin. May increase plasma concentrations of atorvastatin, other statins (e.g. lovastatin) and CYP3A4 substrates w/ narrow therapeutic range (e.g. tacrolimus, sirolimus, everolimus). May increase plasma exposure of metformin. Increased risk of ventricular arrhythmias w/ other drugs that prolong QT interval (e.g. terfenadine, astemizole, mizolastine).
Potentially Fatal: Increased plasma concentrations leading to increased adverse effects w/ CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone). Decreased plasma concentration w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine). Increased risk of QT interval prolongation w/ class 1A (e.g. quinidine) or class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone.
Food Interaction
Increased plasma concentrations w/ grapefruit juice. Decreased plasma concentrations w/ St John's wort.
Tác dụng
Description: Ranolazine exert its antianginal and anti-ischaemic effects through concentration-, voltage-, and frequency-dependent inhibition of the late Na current and other cardiac ion channels and transporters. It may decrease the magnitude of the late Na current resulting in a net reduction in intracellular Na concentrations, reversal of Ca overload, restoration of ventricular pump function, and prevention of ischaemia-induced arrhythmias. Its antianginal effects are not dependent upon reductions in heart rate or BP and QT interval prolongation effect is caused by inhibition of rapid delayed rectifier K current (IKr), which prolongs the ventricular action potential.
Pharmacokinetics:
Absorption: Highly variable. Time to peak plasma concentration: Approx 2-5 hr.
Distribution: Plasma protein binding: Approx 62%.
Metabolism: Extensively metabolised in GI tract and liver by CYP3A4 (major) and CYP2D6 (minor) isoenzymes.
Excretion: Via urine (approx 75%) and the remainder in faeces (<5% as unchanged drug). Terminal half-life: 7 hr.
Bảo quản
Store at 25°C.
Phân loại MIMS
References
Anon. Ranolazine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/08/2014.

Buckingham R (ed). Ranolazine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/08/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Ranolazine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 05/08/2014.

Ranexa Extended-Release Tablets. U.S. FDA. https://www.fda.gov/. Accessed 05/08/2014.

Ranexa Tablet, Film Coated, Extended Release (Gilead Sciences, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/08/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Ranolazine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in